# NCT04704934 (NCT04704934)

> Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04704934
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
- Interventions: Trastuzumab deruxtecan; Ramucirumab; Paclitaxel
- Enrollment: 490
- Primary outcome: Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel

## Commentary we found

- YouTube: 59
- X threads: 43
- Podcasts: 34
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04704934

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04704934", "email": "<work email>"}; the inbox owner confirms by the emailed link.